Concomitant use of the following medications a. Any investigational anticancer therapy. b. Any concurrent chemotherapy, immunotherapy, or biologic therapy. Concurrent use of hormones for non-cancer -related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable. c. Immunosuppressive medications including, but not limited to systemic corticosteroids (>10 mg/day prednisone or equivalent), methotrexate, azathioprine, and tumor necrosis factor alpha (TNF -α) blockers. Use of immunosuppressive medications for the management of investigational product -related AEs, in subjects with contrast allergies is acceptable. In addition, use of inhaled and intranasal corticosteroids is permitted. 13. Known contraindications to radiotherapy 7.0 RECRUITMENT PLAN Eligible patients with malignant pleural or peritoneal mesothelioma will be recruited from the Thoracic Medical Oncology and Radiation Oncology departments at MSKCC. An attending physician of the Thoracic Medical Oncology and Radiation Oncology department will evaluate all patients. Participation is voluntary. The consenting physician will inform patients of their diagnosis, current treatment options, including standard treatment, and the risks, benefits and experimental nature of this treatment program. Memorial Hospital is a major referral center for MPM. In addition, the study information may be placed on the institutional hospital website to maximize r e c r u i t m e n t . Patients under the age of 18 are excluded because this disease does not occur in patients that age, and the safety of these treatments has not been established for them. The Memorial Sloan Kettering Cancer Center IRB Number: 17- 358 A(7) Approval date: 25 -Feb-2022 Page 20 of 51 patient population includes all patients under the care of attending surgical, medical and radiation oncologists at MSKCC main campus or regional sites. Every attempt will be made to recruit women and minorities to participate in this study.